https://www.nzx.com/files/attachments/230971.pdf
A great start for a newly listed company!
Printable View
https://www.nzx.com/files/attachments/230971.pdf
A great start for a newly listed company!
https://www.nzx.com/companies/AFT/announcements/279472
Probably back over $3 now! "significant boost in sales"
AFT has only been listed for just under 3 months, and they have already announced a couple of very positive announcements.
Disclosure: Happy Holder
Doesnt look like a chance, by the depth---You sure like those speculative plays TJ!
https://www.nzx.com/companies/AFT/announcements/279815
Simply stunning, one would think this sort of break through would certainly push it over $3!
I dunno tJ--Im still looking at the depth--sell 4551@285---buy 400@275
Im not surprised they got approval--its a combination of 2 of the most common ingredients around--just doesnt seem like the sort of thing to take the medical world by storm--(no reason not to use it though--Im sure it will keep selling,but I think you will need some sort of breakthrough (from the research)to really make traction.
Right now there is heaps of positivity on the NZX so if it doesnt happen today ,or soon,might be alot of waiting.
Cautiously optimistic. An initial step in what will be a long process for FDA approval in clinical application.
Here's the link to one of their trials from the US if your clinically inclined. https://clinicaltrials.gov/ct2/show/NCT02689063
It is similar to the trial which will be piloted in Christchurch
Speaking to my colleagues in the pain management field, there are still a myriad of issues concerning IV administration of NSAIDs
https://www.nzx.com/companies/AFT/announcements/282071
https://www.nzx.com/companies/AFT/announcements/282070
Solid announcements, leading up to what will hopefully be an impressive full year results announcement on Wednesday May 25 2016 (around 9am)
The big question is just how much dosh they are churning through with the research,and whether they are coming up with anything--I wonder if they would not be better off just promoting their established product(but whats the difference between just taking 1/2 tab of ibuprofen and 1/2 of paracetimal (i did the spell check on the misspelling of para and it told me ''malpractice'' --you gotta laugh sometimes)
Theres probably a big difference but Ive often wondered
I was asked by my chemist what I thought of AFT.
Told him I would find out what I could.
So 96,834,838 shares on issue,giving at $2.95 a market capitalisation of $285,662,772.
Half year to 30th September 2015;
Revenue $29,543,000
Nett loss $6,367,000.
Next report due 25th May .
Conculsion.The market is factoring in a lot of "blue skies".Be careful.
https://www.nzx.com/files/attachments/236150.pdf
On the face of it, what was interesting for me:
- "losses" (when excluding Research and development expenses and Equity accounted loss of joint venture entity) increased slightly from $204k to $564k
- gross profit up almost 12%, with margins reasonably strong (not showing singes of dramatic decreases in gross margin to try sell more!)
- Australia is doing very well (and probably continue to grow in double digits)
- Rest of world will probably continue to treble in sales for the next few years
- NZ is performing "solidly" but will probably continue at mid single digits due to saturation (great to see market share is growing!)
Look forward to hearing what others are thinking, but this looks to be a keeper!
Disclosure: of course I'm holding!
http://www.sharechat.co.nz/article/a...two-years.html
Anyone go?
Presentation didn't look to exciting, but it's good to see things are tracking well
Taking paracetamol and ibuprofen together is effectively the same, and a lot of doctors do actually prescribe this for post-operative pain relief (particularly with the current push to get away from opiate-based analgesics). However, in theory it's best for patient safety and compliance to simplify a prescription as much as possible (one tablet is better than two). As far as over-the-counter use is concerned, I imagine that users who find that a combination is best for their particular pain would also prefer to have a packet of the all-in-one tablet, plus it's safer if the combination dose is pre-measured instead of having a situation where consumers have to mix and match.
What I'm most interested in is whether they have a US sales partner lined up and what sort of marketing effort will be directed toward US healthcare providers.
One day the share price might surge up
Impressive sales chart in annoucement
https://www.nzx.com/files/attachments/243361.pdf